Some Drug Trials Resume after Declines During Pandemic

(Reuters)—Pharmaceutical companies have ramped up clinical trials in the past month, rebounding from a steep decline in activity following the start of the COVID-19 outbreak, though activity remains below pre-pandemic levels, according to new research shareS with Reuters.

The research, which was prepared by clinical trial consulting firm Medidata, shows that new subjects entered trials globally in June at a 30% lower rate than they did before the pandemic. But that is significantly higher than the roughly 70% decline in new subject starts in April.

(Reporting by Carl O’Donnell; Editing by Leslie Adler)